MAPT and Alzheimer disease: Topographic biomarkers are related to the regional consequences of AD pathology, such as regional hypometabolism on fluorodeoxyglucose (FDG)-PET, tau PET, and regional/local atrophy on structural magnetic resonance imaging (MRI).